Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-04-01-Speech-3-257"

PredicateValue (sorted: default)
rdf:type
dcterms:Date
dcterms:Is Part Of
dcterms:Language
lpv:document identification number
"en.20090401.20.3-257"2
lpv:hasSubsequent
lpv:speaker
lpv:spoken text
"Mr President, I would like just to put on the record that there is one amendment which I cannot support as it would, in fact, create a legal impasse. If you cannot administer a drug under test to animals unless it already has an MRL, then you cannot carry out tests that are necessary to obtain the data to establish MRLs and the withdrawal period in the first place. I would like to thank the Commissioner for his cooperation in this area and put on the record the urgent need for review of the Veterinary Medicines Directive. In a sense we are using this MRL review as a bit of a ‘patch and mend’ for a major problem that is under the radar but which we are all very aware of. The availability of an adequate range of veterinary medicines to treat the wide variety of animal species in the European Community has been a growing challenge over the last two decades. During this period, considerable efforts have been made by various stakeholders, including regulators, industry and veterinarians, to address the problems of the availability of medicines. Despite these efforts, the situation has continued to deteriorate. The lack of authorised medicines poses a real threat to animal health and welfare and the safety of consumers. It also raises significant problems for animal owners, farmers, veterinarians and governments if animals are untreated, or treated with an unauthorised or an unsuitable product – including the risk of zoonotic disease implications from untreated or inappropriately treated animals for the animal owners, consumers and citizens. There are also financial, legal and trade implications for the various stakeholders involved, whilst the lack of medicines may have negative effects on rural economies and agriculture generally. An example – and a most important point – is the effect on pollination as a consequence of reduced numbers of bee colonies. Bees are a very important Minor Use/Minor Species (MUMS) issue. However, not only does the current availability problem in the EU have implications across the board for the health and welfare of animals, the security of the Community’s food supply and public health, it also undermines the ability of the EU to meet the Lisbon Agenda and to reap the enormous potential for European agriculture and offshore aquaculture to attract research and development in the veterinary pharmaceutical field. Thank you again to all colleagues and the Commissioner for cooperation on this report."@en1
lpv:spokenAs
lpv:unclassifiedMetadata
lpv:videoURI

Named graphs describing this resource:

1http://purl.org/linkedpolitics/rdf/English.ttl.gz
2http://purl.org/linkedpolitics/rdf/Events_and_structure.ttl.gz
3http://purl.org/linkedpolitics/rdf/spokenAs.ttl.gz

The resource appears as object in 2 triples

Context graph